Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis
Psoriasis is a chronic inflammatory, autoimmune-mediated disease that affects millions of individuals worldwide. Advances in treatment with biological agents represented by monoclonal antibodies, such as TNF-α inhibitors (TNFI), IL-17A and IL-12/23 antagonists have not only benefited from outstandin...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/11/12/1316 |
| _version_ | 1797503000685576192 |
|---|---|
| author | Flavia Anghel Diana Nitusca Patricia Cristodor |
| author_facet | Flavia Anghel Diana Nitusca Patricia Cristodor |
| author_sort | Flavia Anghel |
| collection | DOAJ |
| description | Psoriasis is a chronic inflammatory, autoimmune-mediated disease that affects millions of individuals worldwide. Advances in treatment with biological agents represented by monoclonal antibodies, such as TNF-α inhibitors (TNFI), IL-17A and IL-12/23 antagonists have not only benefited from outstanding clinical efficacy with lower side effects compared to conventional systemic therapy, but also raised the standards towards therapeutic success, fact reflected in the greater Psoriasis Area and Severity Index (PASI) response rates. However, due to their relatively recent introduction in clinical practice, and despite their proven superior efficacy, further research is needed for monitoring the eventual changes in treatment-induced parameters, especially of metabolic origin. In this respect, initial reports stress on one particular comorbidity associated with psoriasis-obesity-which seems to be not only a risk and result of the disease, but also an adverse effect of long-term therapy with some biologics. The consequent drug-induced increase in body mass index (BMI) of patients suffering from psoriasis undergoing biological treatment appears to contribute to the progression of the disease, promote drug discontinuation and reduce overall clinical efficacy of monoclonal antibodies. Therefore, we review herein the impact of body weight (BMI) increase on the biological treatment of psoriasis, to further investigate on its relationship with the disease and aid on the management of treatment schemes that take into account individual characteristics of patients, such as body mass, for a more efficient and personalized therapy approach. |
| first_indexed | 2024-03-10T03:44:14Z |
| format | Article |
| id | doaj.art-c3258a4a2dc64bbcbca5530e7a65671d |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T03:44:14Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-c3258a4a2dc64bbcbca5530e7a65671d2023-11-23T09:13:42ZengMDPI AGLife2075-17292021-11-011112131610.3390/life11121316Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for PsoriasisFlavia Anghel0Diana Nitusca1Patricia Cristodor2Department of Biochemistry and Pharmacology, “Victor Babe” University of Medicine and Pharmacy, Pta Eftimie Murgu Nr. 2, 300041 Timişoara, RomaniaDepartment of Biochemistry and Pharmacology, “Victor Babe” University of Medicine and Pharmacy, Pta Eftimie Murgu Nr. 2, 300041 Timişoara, RomaniaDepartment of Dermatology and Venerology, “Victor Babe” University of Medicine and Pharmacy, Pta Eftimie Murgu Nr. 2, 300041 Timişoara, RomaniaPsoriasis is a chronic inflammatory, autoimmune-mediated disease that affects millions of individuals worldwide. Advances in treatment with biological agents represented by monoclonal antibodies, such as TNF-α inhibitors (TNFI), IL-17A and IL-12/23 antagonists have not only benefited from outstanding clinical efficacy with lower side effects compared to conventional systemic therapy, but also raised the standards towards therapeutic success, fact reflected in the greater Psoriasis Area and Severity Index (PASI) response rates. However, due to their relatively recent introduction in clinical practice, and despite their proven superior efficacy, further research is needed for monitoring the eventual changes in treatment-induced parameters, especially of metabolic origin. In this respect, initial reports stress on one particular comorbidity associated with psoriasis-obesity-which seems to be not only a risk and result of the disease, but also an adverse effect of long-term therapy with some biologics. The consequent drug-induced increase in body mass index (BMI) of patients suffering from psoriasis undergoing biological treatment appears to contribute to the progression of the disease, promote drug discontinuation and reduce overall clinical efficacy of monoclonal antibodies. Therefore, we review herein the impact of body weight (BMI) increase on the biological treatment of psoriasis, to further investigate on its relationship with the disease and aid on the management of treatment schemes that take into account individual characteristics of patients, such as body mass, for a more efficient and personalized therapy approach.https://www.mdpi.com/2075-1729/11/12/1316psoriasisbody mass indexmonoclonal antibodiesdrug-induced weight gain |
| spellingShingle | Flavia Anghel Diana Nitusca Patricia Cristodor Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis Life psoriasis body mass index monoclonal antibodies drug-induced weight gain |
| title | Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis |
| title_full | Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis |
| title_fullStr | Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis |
| title_full_unstemmed | Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis |
| title_short | Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis |
| title_sort | body mass index influence for the personalization of the monoclonal antibodies therapy for psoriasis |
| topic | psoriasis body mass index monoclonal antibodies drug-induced weight gain |
| url | https://www.mdpi.com/2075-1729/11/12/1316 |
| work_keys_str_mv | AT flaviaanghel bodymassindexinfluenceforthepersonalizationofthemonoclonalantibodiestherapyforpsoriasis AT diananitusca bodymassindexinfluenceforthepersonalizationofthemonoclonalantibodiestherapyforpsoriasis AT patriciacristodor bodymassindexinfluenceforthepersonalizationofthemonoclonalantibodiestherapyforpsoriasis |